Surrozen (SRZN) Competitors $9.75 +0.15 (+1.56%) Closing price 04/17/2025 03:59 PM EasternExtended Trading$9.80 +0.05 (+0.51%) As of 04/17/2025 04:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SRZN vs. GLSI, IKT, PRQR, FDMT, NMRA, LRMR, NGNE, SCPH, OGI, and ADCTShould you be buying Surrozen stock or one of its competitors? The main competitors of Surrozen include Greenwich LifeSciences (GLSI), Inhibikase Therapeutics (IKT), ProQR Therapeutics (PRQR), 4D Molecular Therapeutics (FDMT), Neumora Therapeutics (NMRA), Larimar Therapeutics (LRMR), Neurogene (NGNE), scPharmaceuticals (SCPH), Organigram (OGI), and ADC Therapeutics (ADCT). These companies are all part of the "pharmaceutical products" industry. Surrozen vs. Greenwich LifeSciences Inhibikase Therapeutics ProQR Therapeutics 4D Molecular Therapeutics Neumora Therapeutics Larimar Therapeutics Neurogene scPharmaceuticals Organigram ADC Therapeutics Greenwich LifeSciences (NASDAQ:GLSI) and Surrozen (NASDAQ:SRZN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, valuation, dividends and community ranking. Does the media prefer GLSI or SRZN? In the previous week, Greenwich LifeSciences had 2 more articles in the media than Surrozen. MarketBeat recorded 3 mentions for Greenwich LifeSciences and 1 mentions for Surrozen. Surrozen's average media sentiment score of 1.00 beat Greenwich LifeSciences' score of -0.61 indicating that Surrozen is being referred to more favorably in the news media. Company Overall Sentiment Greenwich LifeSciences Negative Surrozen Positive Is GLSI or SRZN more profitable? Surrozen's return on equity of -120.51% beat Greenwich LifeSciences' return on equity.Company Net Margins Return on Equity Return on Assets Greenwich LifeSciencesN/A -185.12% -164.27% Surrozen N/A -120.51%-54.68% Which has preferable valuation & earnings, GLSI or SRZN? Greenwich LifeSciences has higher earnings, but lower revenue than Surrozen. Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGreenwich LifeSciencesN/AN/A-$8.89M-$1.20-7.46Surrozen$10.66M3.00-$43.04M-$21.77-0.45 Do analysts rate GLSI or SRZN? Greenwich LifeSciences presently has a consensus target price of $38.00, indicating a potential upside of 324.58%. Surrozen has a consensus target price of $38.50, indicating a potential upside of 294.87%. Given Greenwich LifeSciences' higher possible upside, equities research analysts plainly believe Greenwich LifeSciences is more favorable than Surrozen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Greenwich LifeSciences 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Surrozen 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, GLSI or SRZN? Greenwich LifeSciences has a beta of 1.76, meaning that its stock price is 76% more volatile than the S&P 500. Comparatively, Surrozen has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500. Do institutionals and insiders hold more shares of GLSI or SRZN? 4.2% of Greenwich LifeSciences shares are owned by institutional investors. Comparatively, 66.6% of Surrozen shares are owned by institutional investors. 51.7% of Greenwich LifeSciences shares are owned by company insiders. Comparatively, 43.5% of Surrozen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the MarketBeat Community believe in GLSI or SRZN? Greenwich LifeSciences received 2 more outperform votes than Surrozen when rated by MarketBeat users. Likewise, 44.44% of users gave Greenwich LifeSciences an outperform vote while only 28.57% of users gave Surrozen an outperform vote. CompanyUnderperformOutperformGreenwich LifeSciencesOutperform Votes844.44% Underperform Votes1055.56% SurrozenOutperform Votes628.57% Underperform Votes1571.43% SummaryGreenwich LifeSciences beats Surrozen on 8 of the 15 factors compared between the two stocks. Get Surrozen News Delivered to You Automatically Sign up to receive the latest news and ratings for SRZN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SRZN vs. The Competition Export to ExcelMetricSurrozenBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$31.98M$2.84B$5.31B$7.35BDividend YieldN/A1.86%5.47%4.31%P/E Ratio-0.4530.4821.9417.82Price / Sales3.00441.91380.9497.72Price / CashN/A168.6838.3134.64Price / Book0.533.466.453.98Net Income-$43.04M-$72.06M$3.22B$247.81M7 Day Performance9.74%2.57%5.85%3.19%1 Month Performance-17.30%-15.93%-9.58%-7.70%1 Year Performance3.67%-25.72%11.85%1.49% Surrozen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SRZNSurrozen3.5955 of 5 stars$9.75+1.6%$38.50+294.9%+3.7%$31.98M$10.66M-0.4580Short Interest ↓Positive NewsGap UpGLSIGreenwich LifeSciences1.5163 of 5 stars$9.59+8.6%$38.00+296.2%-25.8%$126.06MN/A-11.993Earnings ReportUpcoming EarningsGap DownHigh Trading VolumeIKTInhibikase Therapeutics1.0351 of 5 stars$1.68-8.7%$6.50+286.9%-7.1%$124.90M$260,000.00-0.636Gap UpPRQRProQR Therapeutics2.3657 of 5 stars$1.17-0.8%$9.50+712.0%-42.7%$123.10M$18.91M-3.66180Short Interest ↓News CoverageFDMT4D Molecular Therapeutics2.8071 of 5 stars$2.65-4.3%$26.71+908.1%-87.9%$122.70M$37,000.00-0.93120Analyst RevisionNews CoverageNMRANeumora Therapeutics3.1586 of 5 stars$0.75+2.3%$9.29+1,132.8%-93.6%$122.00MN/A-0.40108LRMRLarimar Therapeutics3.2105 of 5 stars$1.87-4.6%$19.63+949.5%-70.8%$119.73MN/A-1.6330Positive NewsNGNENeurogene2.3142 of 5 stars$7.86-10.6%$53.00+574.3%-62.3%$117.35M$925,000.00-1.8490Gap DownHigh Trading VolumeSCPHscPharmaceuticals3.7835 of 5 stars$2.33+0.4%$14.00+500.9%-43.6%$117.16M$36.33M-1.2330Short Interest ↓Gap DownOGIOrganigram0.6432 of 5 stars$0.92-2.7%N/A-43.4%$116.74M$166.12M-2.43860Positive NewsADCTADC Therapeutics2.1665 of 5 stars$1.17-1.3%$7.75+565.2%-74.3%$115.43M$70.84M-0.49310 Related Companies and Tools Related Companies GLSI Competitors IKT Competitors PRQR Competitors FDMT Competitors NMRA Competitors LRMR Competitors NGNE Competitors SCPH Competitors OGI Competitors ADCT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SRZN) was last updated on 4/20/2025 by MarketBeat.com Staff From Our PartnersClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredTrump’s Top Secret $9 Trillion AI SuperweaponJeff Brown spotted Nvidia at $1. Now he’s revealing a new AI superweapon — and the Musk-connected stocks that ...Brownstone Research | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredM.A.G.A. is Finished – This Could be even BetterYou’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big ch...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Surrozen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Surrozen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
